Fulcrum Therapeutics (FULC) Superinvestor holders
10 of the superinvestors we track hold Fulcrum Therapeutics (FULC) in their latest 13F filings, $54M in total.
Summary
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $20M, 1.2% of the portfolio.
In their latest quarter: 1 opened a new position, 5 added, 4 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Wilmot Harkey Nantahala Capital Management |
Added | 5,475,040 | $20M | 1.2% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 3,044,385 | $11M | 0.0% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Added | 1,647,800 | $6M | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace |
New position | 1,358,423 | $5M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 1,103,261 | $4M | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 812,766 | $3M | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
Trimmed | 701,007 | $3M | 0.0% | Q3 2026 |
| Steve Cohen Point72 Asset Management |
Trimmed | 651,427 | $2M | 0.0% | Q2 2026 |
| Ken Tropin Graham Capital Management |
Trimmed | 25,067 | $91,745 | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
Trimmed | 13,098 | $47,939 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 10 |
| Q1 2026 | 10 |
| Q4 2025 | 10 |
| Q3 2025 | 6 |
| Q2 2025 | 9 |
| Q1 2025 | 7 |
| Q4 2024 | 6 |
| Q3 2024 | 7 |
Questions about Fulcrum Therapeutics
Which superinvestors own Fulcrum Therapeutics?
10 of the superinvestors we track hold Fulcrum Therapeutics (FULC) in their latest 13F filings, $54M in total. Wilmot Harkey, David Shaw, Jim Simons, Paul Marshall, Cliff Asness, Two Sigma.
Who is the largest superinvestor holder of FULC?
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $20M, 1.2% of the portfolio.
From Fulcrum Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.